CNTG News and Press, Centogene N.V. From 07/27/21

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the appointment of Dr. Patrice P. Den&#x...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the voting results of the Company’...

Company outlines significant value creation potential to contribute to the diagnosis of rare diseases and to enable the development of novel therapeutics Focuses on leveraging its unique rare disease-centric Bio/Databank to accelerate orphan drug development in partnership with bio-/p...

Centogene (CNTG): Q1 Revenue of €65M (+437.2% Y/Y)Based on the trajectory at the end of Q1 2021, CENTOGENE anticipates revenues from the COVID-19 testing segment to be at least on par with 2020.Press Release For further details see: Centogene reports Q1 results

Recorded revenues of €65.0 million in Q1 2021, driven by revenues from COVID-19 testing, up over 400% compared to €12.1 million in Q1 2020 Achieved positive adjusted EBITDA, driven by COVID-19 testing revenues, while continuing to invest in the Company’s rare ...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 09, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 07, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced today that it will be holding a Virtual Invest...

Centogene N.V. (CNTG) announces a new observational study to understand the prevalence of genetic mutations in patients with frontotemporal dementia ((FTD)).The observational EFRONT Study is being conducted with Alector (ALEC) under a commercial agreement.Financial details of the deal are not...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 02, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced a new observational study to understand ...

World leader and trusted partner in rare diseases releases enhanced Whole Exome Sequencing (WES) solution to improve diagnosis in complex and unsolved patient cases NEW CentoXome® provides best-in-class clinical insights based on CENTOGENE’s unique rare disease-centric Bio...